Aragon Pharmaceuticals, Inc. et al v. Lupin Limited et al
| Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. and Sloan Kettering Institute for Cancer Research |
| Lupin Limited and Lupin Pharmaceuticals, Inc. |
| 1:2022cv00637 |
| May 13, 2022 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on June 3, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 9 STIPULATION TO EXTEND TIME for Defendants to answer, move or otherwise respond to the Complaint (D.I. 1) to August 15, 2022 - filed by Lupin Limited, Lupin Pharmaceuticals, Inc.. (Phillips, John) |
SO ORDERED, re #9 STIPULATION TO EXTEND TIME for Defendants to answer, move or otherwise respond to the Complaint (D.I. 1) to August 15, 2022, filed by Lupin Limited, Lupin Pharmaceuticals, Inc. Reset Answer Deadlines: Lupin Limited answer due 8/15/2022; Lupin Pharmaceuticals, Inc. answer due 8/15/2022. Ordered by Judge Colm F. Connolly on 6/3/2022. (kmd)
|
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (nms) |
| Filing 8 AFFIDAVIT of Service for Summons, Complaint and related papers served on Lupin Limited on May 17, 2022, filed by Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research. (Tigan, Jeremy) |
| Filing 7 SUMMONS Returned Executed by Janssen Biotech, Inc., Aragon Pharmaceuticals, Inc., Sloan Kettering Institute for Cancer Research. Lupin Pharmaceuticals, Inc. served on 5/16/2022, answer due 6/6/2022. (Blumenfeld, Jack) |
| Filing 6 Summons Issued as to Lupin Limited on 5/13/2022; Lupin Pharmaceuticals, Inc. on 5/13/2022. (Attachments: #1 Summons Issued)(apk) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. filed by Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research. (apk) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,481,663 B2. (apk) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 4/4/2022. Date of Expiration of Patent: 6/4/2033.Thirty Month Stay Deadline: 8/14/2025. (apk) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) |
| Filing 1 COMPLAINT filed against Lupin Limited, Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-3873367.) - filed by Janssen Biotech, Inc., Aragon Pharmaceuticals, Inc., Sloan Kettering Institute for Cancer Research. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(apk) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
